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Abstract
Background: The interaction between the membrane glycoprotein, CD200 and its cognate receptor CD200
receptor (CD200R), has been shown to play a role in maintaining microglia in a quiescent state. There is evidence
of increased activation under resting and stimulated conditions in microglia prepared from CD200-deficient mice
compared with wild-type mice, whereas activation of the receptor by CD200 fusion protein (CD200Fc) ameliorates
inflammatory changes which are evident in the central nervous system (CNS) of the mouse model of multiple
sclerosis (MS), experimental autoimmune encephalomyelitis (EAE) and also in the hippocampus of aged rats.
Additionally, an inverse relationship between microglial activation and expression of CD200 has been observed in
animals treated with lipopolysaccharide (LPS) or amyloid-β (Aβ).
Methods: We assessed the effect of CD200R activation by CD200Fc on Aβ-induced production of the pro-
inflammatory cytokines, interleukin-1β (IL-1β) and tumor necrosis factor-α (TNFα) and the expression of microglial
activation markers, CD68 and CD40 in cultured glia. The role played by downstream of tyrosine kinase 2 (Dok2)
phosphorylation in mediating the effects of CD200R activation was evaluated by siRNA knockdown of Dok2. To
further examine the impact of inflammatory changes on synaptic plasticity, the effect of CD200Fc on Aβ-induced
impairment of long-term potentiation (LTP) in the CA1 region of hippocampal slices was also investigated.
Results: We demonstrate that Aβ-induced increases in IL-1β, TNFα, CD68 and CD40 were inhibited by CD200Fc.
The evidence suggests that Dok2 phosphorylation is a key factor in mediating the effect of CD200Fc, since Dok2
knockdown by siRNA abrogated its effects on microglial activation and inflammatory cytokine production.
Consistent with evidence that inflammatory changes negatively impact on LTP, we show that the Aβ-induced
impairment of LTP was attenuated by CD200Fc.
Conclusions: The findings suggest that activation of CD200R and Dok2 is a valuable strategy for modulating
microglial activation and may have therapeutic potential in neurodegenerative conditions.
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Introduction
It is accepted that neuroimmune regulatory proteins,
which are expressed on many cells, interact with their
receptors on microglia and play an important role in
modulating the activity of these cells. One of the most-
studied ligand-receptor pairs is CD200-CD200 receptor
(CD200R). In common with other ligand-receptor pairs,
CD200 is widely expressed, whereas receptor expression
is confined primarily to cells of the myeloid lineage [1,2].
In the CNS, CD200 is expressed on neurons [3,4] and
astrocytes [5,6]. Compelling evidence for a modulatory
role for CD200-CD200R interaction has been obtained
from the study of changes in CD200-deficient mice.
Under resting conditions, the number of activated
microglia is increased in the brain of these mice [7] and
they exhibit exaggerated responses to inflammatory chal-
lenge from lipopolysaccharide (LPS) and amyloid-β (Aβ)
[4,8], due possibly to increased relative expression of
Toll-like receptors (TLR) 2 and 4 [7].
Exacerbated symptoms of disease have been reported
with evidence of enhanced inflammatory changes in ani-
mal models of multiple sclerosis [9] and Parkinson’s dis-
ease [10]. A key change in these experimental conditions
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is increased microglial activation and, in these models as
well as others, including Toxoplasma gondii-induced en-
cephalitis [11], facial nerve transaction [9] and experi-
mental autoimmune uveoretinitis [12], greater microglial
activation was observed in CD200-deficient, compared
with wild-type mice. Consistently, an inverse relationship
between microglial activation and CD200 has been
described in the brain of aged animals [4], in animals
following ischaemic insult and in Aβ- [4] and LPS-trea-
ted animals [8].
Activation of CD200R by a CD200Fc has also been
shown to decrease the symptoms of experimental auto-
immune encephalomyelitis (EAE) and the associated ac-
tivation of microglia/macrophages [13], and this has
been reflected in its ability to decrease the inflammatory
changes observed in collagen-induced arthritis [14,15].
Similarly we have recently shown that intracerebroven-
tricular injection of CD200Fc decreased expression of
markers of microglial activation in the hippocampus of
aged rats [5].
The 67 amino acid cytoplasmic tail of CD200R con-
tains an NPXY signaling motif with three tyrosine resi-
dues; the interaction between CD200 and CD200R
induces phosphorylation of these residues initiating a
signaling cascade [16]. The adaptor proteins, Dok1 and
Dok2, are recruited to the complex leading to activation
of RasGAP and SH2-containing inositol phosphatase
(SHIP) [17]. At least in the case of U937 cells, it appears
that the modulatory effect of CD200R activation on IL-8
production is mediated by recruitment of Dok2 and Ras-
GAP activation [17]. Thus, knockdown of Dok2, but not
Dok1, ameliorated the increase in IL-8 production fol-
lowing CD200R activation.
Here we assessed the effect of CD200Fc on Aβ-
induced changes in glia, showing that it inhibited micro-
glial activation and that these changes were mediated via
Dok2 phosphorylation.
Methods
Preparation and treatment of primary glial cultures
Mixed glial cultures were prepared from one-day-old
C57BL/6 mice as previously described [4]. These cul-
tures contained approximately 70% astrocytes and 30%
microglia as measured by assessing CD11b expression
using flow cytometry [7].
To prepare purified microglia, cells were seeded onto
25 cm2 flasks and, after 24 hours, media was replaced
with cDMEM containing GM-CSF (10 ng/ml) and M-CSF
(20 ng/ml). After 10 days in culture, non-adherent
microglia were harvested by shaking (110 rpm, two
hours, room temperature), tapping and centrifuging
(2,000 rpm, five minutes). The pellet was resuspended in
cDMEM, the microglia were plated onto 24-well plates
at a density of 1 x 105 cells/ml and maintained at 37°C
in a 5% CO2 humidified atmosphere for up to three days
prior to treatment.
To prepare purified astrocytes, flasks containing the
adherent astrocytes were washed with sterile PBS and
2 ml of 0.05%w/v trypsin–EDTA was added at 37°C.
DMEM was then added to inhibit the trypsin, the cells
were centrifuged at 2,000 g for three minutes and the
pellet was resuspended in DMEM. Cells were plated in
six-well plates at a density of 2 × 105 cells/ml.
Cells were incubated in the presence or absence of
Aβ[1–40] (4.2 μM) plus Aβ[1–42] (5.6 μM) for 24 hours. In
various experiments, supernatant was taken for later
analysis of cytokines, and cells were harvested for ana-
lysis by FACS, for preparation of mRNA to assess ex-
pression of markers of microglial activation or cytokines,
or for preparation of cell lysate to assess expression of
proteins by Western immunoblotting. In some experi-
ments, mixed glia were pre-incubated with CD200Fc
(2.5 μg/ml, R & D Systems, Minneapolis, MN, USA for
30 minutes prior to Aβ treatment.
Analysis of cell surface markers by flow cytometry
Mixed glial cells were trypsinized (0.25% Trypsin-EDTA,
Sigma, Gillingham, UK), washed three times in FACS
buffer (2% FBS, 0.1% NaN3 in PBS) and blocked for 15
minutes at room temperature in FACS block (1:500 in
FACS buffer; Mouse BD Fc Block, BD Pharmingen, Ox-
ford, UK). Cells were incubated with APC-rat anti-mouse
CD11b (1:400 in FACS buffer; BD Biosciences, Oxford,
UK), FITC-rat anti-mouse CD40 (1:200 in FACS buffer;
BD Biosciences, UK) and FITC-rat anti-mouse CD68
(1:200 in FACS buffer; AbD Serotec, Oxford, UK), and
PE-rat anti-mouse CD200R (1:200 in FACS buffer;
Abcam, Cambridge, UK). To evaluate phagocytic activity
in microglia, cells were incubated in the presence of
carboxylate-modified polystyrene latex beads (1:200 in
FACS buffer; fluorescent yellow-green, mean particle
size; 1 μm; Sigma, UK) and uptake into CD11b+ cells was
measured. Immunofluorescence analysis was performed
on a DAKO Cyan ADP 7 color flow cytometer (DAKO
Cytomation, Stockport, UK {) with Summit v4.3 software
(Beckman-Coulter, High Wycombe, UK).
Analysis of expression of CD200R, CD68, CD40, IL-1β,
TNFα and MIP-1a mRNA
Total RNA was extracted from harvested glial cells using
a NucleoSpinW RNAII isolation kit (Macherey-Nagel Inc.,
Duren, Germany) and cDNA synthesis was performed on
1 μg total RNA using a High Capacity cDNA RT kit (Ap-
plied Biosystems, Darmstadt, Germany); the protocols
used were according to the manufacturer’s instructions.
Real-time PCR was performed as described previously [4]
using an ABI Prism 7300 instrument (Applied Biosystems,
Germany); the assay IDs were as follows: CD40
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(Mm00441891_m1), CD68 (Mm03047341_m1), CD11b
(Mm00434455_m1), IL-1β (Mm00434228_m1), TNFα
(Mm00443258_m1), CD200R (Mm00491164_m1) and
MIP-1α (Mm00442346_m1). Samples were assayed in du-
plicate and gene expression was calculated relative to the
endogenous control samples (β-actin) to give an RQ value
(2− DDCt, where CT is the threshold cycle).
Assessment of supernatant concentrations of IL-1β and
TNFα
IL-1β and TNFα were assessed by ELISA as previously
described [4] (Duoset, R & D Systems, Minneapolis,
MN, USA). Briefly, standards or supernatant samples
(100 μl) were added to antibody-coated 96-well plates
and incubated for two hours at room temperature, plates
were washed and samples were incubated in detection
antibody for two hours. Plates were washed and incu-
bated in horseradish peroxidase-conjugated streptavidin
(1:200 in PBS containing 1% BSA) for 20 minutes at
room temperature. Substrate solution (tetramethylbenzi-
dine, Sigma, UK) was added, incubation continued at
room temperature in the dark for 30 minutes and the re-
action was stopped using 1 M H2SO4. Absorbance was
read at 450 nm, values were corrected for protein and
expressed as pg/ml protein.
Assessment of CD200 expression and Dok2
phosphorylation by Western immunoblotting
Aβ-treated microglia were harvested in lysis buffer
(50 ml; composition in mM: Tris–HCl 10, NaCl 50,
Na4P2O7.H2O 10, NaF 50, 1% Igepal, phosphatase inhibi-
tor cocktail II and III, protease inhibitor cocktail; all
Sigma, UK) and stored at −20°C. For analysis, samples
were added to 4x SDS sample buffer (composition: Tris–
HCl 100 mM, pH 6.8, 4% SDS, 2% bromophenol blue,
20% glycerol; all Sigma, UK) and heated to 95°C for five
minutes. Samples were separated on 4 to 20% Bis-Tris
gels (Invitrogen, Paisley, UK). Proteins were transferred
to nitrocellulose membrane (Schleicher and Schuell,
Dassel, Germany) and blocked for one hour in Tris-
buffered-saline-0.05% Tween 20 (TBS-T) and 5% non-fat
dried milk/TBS-T at room temperature. Membranes
were incubated overnight at 4°C with anti-Phospho-
Dok2 (1:1,000; R & D Systems, USA) or b-actin (1:5,000;
Sigma, UK) in 2% non-fat dried milk/TBS-T, washed, and
incubated with a horseradish peroxidase (HRP) conju-
gated anti-goat antibody (1:5,000; Jackson Immunore-
search, West Grove, PA, USA) in 2% non-fat dried milk/
TBS-T for 1.5 h.
Aβ-treated astrocytes were harvested as described and
CD200 expression assessed by probing membranes with
anti-CD200 antibody (1:2,000; R & D Systems, USA) in
2% non-fat dried milk/TBS-T, washed, and incubated
with a HRP conjugated anti-goat antibody (1:5,000;
Jackson Immunoresearch, West Grove, PA, USA) in 2%
non-fat dried milk/TBS-T for 1.5 h.
Immunoreactive bands were detected using Immobi-
lon Western chemiluminescent substrate (Millipore, Bill-
erica, MA, USA) and images captured using the Fujifilm
LAS-4000 imager imager (Brennan and Co., Dublin, Ire-
land). To quantify expression of the proteins in some
cases, densitometric analysis was carried out using Ima-
geJ (http://rsbweb.nih.gov/ij/) (National InstituteS of
Health, Bethesda, MD, USA) . Values are presented as
mean ± S.E.M., normalized to β-actin.
RNA interference
Custom ON-TARGET plus smart pool small interfering
RNA (siRNA) targeting mouse Dok2 (Gen bankTM ac-
cession number NM_010071) was purchased from Dhar-
macon (Lafayette, CO, USA). Primary microglial cells
were transfected with Dok2 siRNA (5 nM) using Dhar-
maFECT 1 transfection reagent (Dharmacon). After 72
hours (52% Dok2 knockdown), cells were pre-treated
with CD200Fc prior to Aβ treatment. A control siRNA
duplex containing at least four mismatches of any mouse
gene (ON-TARGET plus Non-targeting siRNA) was
used in parallel experiments. Effective Dok2 knockdown
was determined using confocal microscopy and Western
blotting.
Analysis of LTP in hippocampal slices
Hippocampal slices (400 μm), were prepared from male
C57BL/six mice (five to seven months old), using a
McIlwain tissue chopper (Mickle Laboratory, Surrey,
UK). Slices were maintained in oxygenated artificial
cerebrospinal fluid (aCSF; composition in mM: 125
NaCl, 1.25 KCl, 1 CaCl2, 1.5 MgCl2, 1.25 KH2PO4, 25
NaHCO3, and 10 D-glucose) at room temperature (21 to
23°C) in a holding chamber for a minimum of one hour
before being transferred to a submersion recording
chamber, where they were perfused with oxygenated
aCSF (containing 2 mM CaCl2; 2–3 ml/min; 21 to 23°C).
The Schaffer collateral-commissural pathway was stimu-
lated at 0.033 Hz (0.1 ms duration; approximately 50%
of maximal EPSP amplitude) using a bipolar tungsten
stimulation electrode (Advent Materials, Oxford, UK).
Field excitatory postsynaptic potentials (EPSPs) were
recorded from the CA1 stratum radiatum using a mono-
polar glass recording electrode filled with aCSF. Stable
baseline EPSPs were recorded for 15 to 20 minutes prior
to application of theta-burst stimulation (TBS; 10 trains
(4 pulses at 100 Hz) repeated at 5 Hz) or pharmaco-
logical agents. Aβ[1–40] (500 nM) was applied to the per-
fusate 40 minutes prior to delivery of TBS. In a separate
group of experiments, slices were perfused with
CD200Fc (2 mg/ml) for 20 minutes prior to application
of Aβ. As an additional control, slices were treated with
Lyons et al. Journal of Neuroinflammation 2012, 9:107 Page 3 of 11
http://www.jneuroinflammation.com/content/9/1/107
mouse IgG (2 mg/ml; Sigma, UK) for 20 minutes prior
to Aβ application. Data were acquired using WinWCP
v4.0.7 software (Dr. J. Dempster, Strathclyde, UK) and
evoked EPSPs were normalised to the mean EPSP slope
recorded in the five-minute period prior to LTP induc-
tion. LTP was measured as a mean value of the final five
minutes of recording (55 to 60 minutes post-TBS).
Statistical analysis
Where appropriate, data were analyzed using Student’s
t-test for independent means. In most cases, data were
evaluated using analysis of variance (ANOVA) followed
by post hoc Student Newman–Keuls test to determine
which conditions were significantly different from each
other. Data are expressed as means with standard errors.
Results
Aβ modulates CD200R-associated signaling
CD200 is expressed on many cells, including neurons
and astrocytes [3,5], whereas CD200R is expressed pri-
marily on cells of the myeloid lineage, including micro-
glia [4,9]. Here we report that incubation of astrocytes in
the presence of Aβ decreased CD200 as shown by West-
ern blot (**P< 0.01; Student’s t-test; Figure 1A). Incuba-
tion of microglia in the presence of Aβ increased
CD200R mRNA (*P< 0.05; Student’s t-test; Figure 1B)
and the number of CD11b+ cells that expressed CD200R
(**P< 0.01; Student’s t-test; Figure 1C). Activation of
CD200R plays a role in maintaining microglia in a
quiescent state [4] and the evidence suggests that, at
least in macrophages [17,18], this relies on activation of
Dok2. Whereas Aβ decreased phosphorylation of Dok2
in mixed glial cells (Figure 1D), CD200Fc increased
phosphorylation of Dok2 in a time-dependent manner
(Figure 1E).
CD200Fc attenuated the Aβ-induced increases in markers
of microglial activation and phagocytosis
Aβ significantly increased CD68 mRNA (**P< 0.01;
ANOVA; Figure 2A) and this effect was attenuated in
Aβ-treated cells incubated with CD200Fc (+P< 0.05;
ANOVA). To assess whether the change in gene expres-
sion translated into a change in expression of CD68 on
microglia, cells were evaluated using FACS and the data
indicated that Aβ significantly increased the number
of CD11b+ cells which stained positively for CD68
(**P< 0.01; ANOVA; Figure 2B). The Aβ-induced effect
was attenuated by CD200Fc but the effect did not reach
statistical significance. CD40, another marker of micro-
glial activation, was similarly modulated by Aβ and
CD200Fc; thus Aβ significantly increased CD40 mRNA
and the number of CD11b+ cells which stained positively
for CD40 (***P< 0.001; ANOVA), while CD200Fc sig-
nificantly attenuated the Aβ-induced effects (++P< 0.01;
+++P< 0.001; ANOVA; Figure 2C, D).
Microglia can adopt many activated phenotypes, one
of which is a phagocytic phenotype and the present data
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Figure 1 Aβ modulates CD200R-associated signaling. A. Incubation of purified astrocytes in the presence of Aβ decreased CD200 expression
as illustrated in the sample immunoblot and in the densitometric data (**P< 0.01; Student’s t-test for independent means; n = 6). B and C. Aβ
significantly increased CD200R mRNA on purified microglia (B) and the percentage of CD200R+ CD11b+ cells (C; *P< 0.05; **P< 0.01;
Student’s t-test for independent means; n = 6). D and E. Whereas Aβ decreased Dok2 phosphorylation (D), CD200Fc increased its phosphorylation
in a time-dependent manner (E).
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markers of activation, Aβ also increases phagocytic activ-
ity. Phagocytosis, assessed by evaluating engulfment of
fluorescently-labeled latex beads by CD11b+ cells, was
significantly increased by Aβ (***P< 0.001; ANOVA;
Figure 3); CD200Fc ameliorated the Aβ-induced effect
(+P< 0.05; ANOVA) suggesting that the signaling events
triggered by CD200R activation modulate microglial
phagocytic function.
Activated microglia also release inflammatory cyto-
kines and, in parallel with the changes in markers of
microglial activation and phagocytic function, Aβ signifi-
cantly increased IL-1β and TNFα mRNA expression in
cells (***P< 0.001; ANOVA; Figure 4A, C) and release of
both cytokines from mixed glia (*P< 0.05; ***P< 0.001;
ANOVA; Figure 4B, D). The data indicate that CD200Fc
significantly attenuated these Aβ-induced changes
(+P< 0.05; ++P< 0.01; +++P< 0.001; ANOVA).
Dok2 mediated the effects of CD200Fc
The mechanism by which CD200Fc modulates Aβ-
induced changes is unclear but activation of CD200R
results in phosphorylation of Dok2 and the evidence
suggests that this is pivotal for the negative effects of
CD200 on microglial function [17,18]. To evaluate
whether these signaling events underlie the modulatory
effect of CD200Fc on Aβ, the effect of dok2 siRNA was
assessed. The efficiency of Dok2 knockdown was
assessed by Western blot (Figure 5A) and immuno-
fluoresence (Figure 5B). The quantitative data obtained
from Western immunoblotting indicated that there was
52% reduction in Dok2 expression relative to a non-tar-
geted control siRNA (*P< 0.05; ANOVA; Figure 5A),
whereas immunofluorescent images suggested that the
reduction was greater. The effect of Dok2 knock-down
was assessed on expression of CD40 mRNA and on
cytokine release. Aβ significantly increased CD40 mRNA
(**P< 0.01; ANOVA; Figure 5C) and this effect was atte-
nuated by including CD200Fc in the incubation medium
(++P< 0.01; ANOVA), mirroring the data presented in
Figure 2. However, this modulating effect of CD200Fc
was partially attenuated in Dok2 siRNA-treated cells;
thus there was a significant difference in CD40 mRNA
expression in cells which were incubated in Aβ+
CD200Fc compared with those incubated in the pres-
ence of Aβ+CD200Fc +Dok2 siRNA (}P< 0.05;
ANOVA; Figure 5C). We also assessed supernatant con-
centrations of IL-1β and TNFα and the results show a
similar pattern. Incubation of cells in the presence of Aβ
significantly increased IL-1β and TNFα (***P< 0.001;
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Figure 2 CD200Fc attenuated the Aβ-induced increases in markers of microglial activation. Incubation of mixed glia in the presence of Aβ
significantly increased expression of CD68 mRNA (A) and CD40 mRNA (C; **P< 0.01; ***P< 0.001; ANOVA; n = 6). Aβ also increased the
percentage of CD11b+ cells which expressed CD68 (B) and CD40 (D; ***P< 0.001; ANOVA; n = 6). Addition of CD200Fc to the incubation medium
significantly attenuated the Aβ-induced changes in CD68 mRNA, CD40 mRNA and the percentage of CD11b+ cells which expressed CD40
(+P< 0.05; ++P< 0.01; +++P< 0.001).
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CD200Fc (+P< 0.05; ANOVA). Pretreatment of cells
with Dok2 siRNA prevented the modulating effect of
CD200Fc so that there was a significant difference in
cytokine concentration in supernatant prepared from
cells treated with Aβ+CD200Fc compared with those
treated with Aβ+CD200Fc +Dok2 siRNA (}P< 0.05;
ANOVA).
CD200Fc relieves the Aβ-mediated deficit in LTP
It is well established that inflammatory changes nega-
tively impact on LTP [19] and also that LTP is inhibited
by Aβ [20]. We considered that inhibiting the Aβ-
induced inflammatory changes by CD200Fc may result
in restoration of LTP. Here we confirm that LTP in hip-
pocampal slices was significantly impaired in response to
application of Aβ (***P< 0.001; ANOVA) and show that
this deficit was significantly attenuated when Aβ was ap-
plied in the presence of CD200Fc (*P< 0.05; ANOVA;
Figure 6). The detrimental effects of Aβ on LTP were
not alleviated in the presence of a control mouse IgG
(data not shown).
Discussion
The CNS is protected from insult by several mechanisms
and one of these is the control of microglial activation
by neuroimmune regulatory molecules. The significant
finding of this study is that CD200Fc ameliorates the
Aβ-induced microglial activation and production of in-
flammatory cytokines, and that this is dependent on
Dok2 phosphorylation.
The absence of CD200 is associated with increased in-
flammation and symptoms in EAE and collagen-induced
arthritis [9] and the evidence indicates that CD200Fc
ameliorates these changes [13-15,21]. CD200Fc has also
been shown to inhibit mast cell degranulation [22], to at-
tenuate IFNγ- and IL-17-induced cytokine secretion
from peritoneal cells [23] and to decrease LPS-induced
activation of microglia prepared from spinal cord [13].
The present findings reveal that CD200Fc modulates
Aβ-induced microglial activation and production of
cytokines from these cells. Significantly, this is coupled
with the ability of CD200Fc to attenuate the Aβ-induced
inhibition of LTP. The importance of this finding is that
it may offer a strategy to decrease microglial activation,
and the consequences of the associated inflammatory
changes, which appears to contribute to the pathogen-
esis of Alzheimer’s disease (AD).
The mechanism underlying CD200R-mediated signal-
ing is distinct from most inhibitory receptors which con-
tain immunoreceptor tyrosine-based inhibitory motifs
(ITIM) and consequently signal through recruitment of
Src homology 2 domain containing phosphatases (SHP).
Instead, CD200R-triggered signaling relies on recruit-
ment and subsequent phosphorylation of Dok [17]. The
present data indicate that CD200Fc triggers Dok2 activa-
tion in microglia and we, therefore, investigated the pos-
sibility that knocking down Dok2 might prevent the
ability of CD200Fc to modulate Aβ-induced changes.
The data confirmed that CD200Fc attenuated the Aβ-
induced up-regulation of CD40 mRNA expression and
the release of IL-1β and TNFα from glia and importantly
demonstrated that the effect of CD200Fc was blocked in
cells that were incubated in the presence of Dok2
siRNA. We can conclude that in microglia the CD200R-
mediated modulatory effects are dependent on Dok2
phosphorylation. However, Dok1 and Dok2 are both
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Figure 3 CD200Fc attenuated the Aβ-induced increase in
phagocytosis. A. Incubation of mixed glia in the presence of Aβ
significantly increased the number of cells that internalized
fluorescently-labeled latex beads (compare top two panels) and,
although CD200Fc alone had no impact on latex bead
internalization (bottom left-hand panel), CD200Fc attenuated the
Aβ-induced change (compare right-hand panels). B. Mean data
indicated a significant effect of Aβ on internalization of
fluorescently-labelled latex beads (***P< 0.001; ANOVA; n = 6) which
was significantly attenuated by CD200Fc (+P< 0.05; ANOVA).
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previous evidence has indicated that stimulating macro-
phages prepared from Dok1−/− or Dok2−/− mice with
LPS resulted in a greater production of nitric oxide,
increased the number of TNFα-producing cells and
markedly increased ERK phosphorylation [24]. While
CD200R engagement triggers phosphorylation of both
adaptor proteins [17,18], recent evidence indicates that
activation and recruitment of Dok2 and the subsequent
activation of RasGAP are the key events in CD200R-
induced immune regulatory function in myeloid cells
[17]; the present data are broadly consistent with these
findings. Interestingly, kinetic analysis using U937 macro-
phages suggests that Dok1 negatively regulates Dok2
with evidence indicating that when Dok1 is knocked
down, phosphorylation of Dok2 is increased and recruit-
ment of RasGAP is enhanced [18].
The ability of Aβ to induce microglial activation is
well-documented [25-27] and indeed this action of Aβ,
and the ensuing inflammatory changes, has been pro-
posed as one mechanism which may contribute to the
pathogenesis of Alzheimer’s disease [28]. However, the
molecular changes that trigger Aβ-induced microglial
activation are still poorly understood, thus limiting the
development of strategies which may reduce its negative
effects. Previously, we have reported that the microglial
activation induced by Aβ in vivo was accompanied by a
decrease in CD200 expression on neurons [4] raising the
possibility that interaction of CD200 with CD200R may
modulate Aβ-induced changes. Here we show that Aβ
decreases CD200 expression of astrocytes as well as neu-
rons and that, in the context of mixed glia, the inter-
action between CD200 on astrocytes and CD200R on
microglia is a significant factor in controlling microglial
activation. We used CD200Fc to stimulate CD200R and
the data show that incubating cells in its presence is cap-
able of reducing expression of markers of microglial acti-
vation in Aβ-treated cells. Both CD40 and CD68 mRNA
were increased in Aβ-treated mixed glia, and import-
antly, FACS analysis revealed that these changes were
mirrored by increased expression of both markers on
CD11b+ microglia. Incubating cells in the presence of
CD200Fc attenuated these Aβ-induced changes. Simi-
larly, Aβ increased the expression and release of IL-1β
and TNFα as previously reported [27] and CD200Fc also
attenuated these changes.
In addition to their ability to up-regulate cell surface
markers of activation and inflammatory cytokines and
chemokines, activated microglia may also exhibit
increased phagocytosis. In this study, phagocytosis of
fluorescently-labelled latex beads by CD11b+ cells was
increased by Aβ. This finding is similar to previous
observations in which Aβ was shown to increase phago-
cytosis of fluorescent microspheres, albeit in BV2 cells
rather than primary glial cells [29,30]. In parallel with its
ability to exert an inhibitory effect on Aβ-induced changes,
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Figure 4 CD200Fc attenuated the Aβ-induced increases in IL-1β and TNFα. Incubation of mixed glia in the presence of Aβ significantly
increased expression of IL-1β mRNA (A) and TNFα mRNA (C; ***P< 0.001; ANOVA; n = 6). Aβ also increased supernatant concentrations of IL-1β
(B) and TNFα (D; *P< 0.05; ***P< 0.001; ANOVA; n = 6). Addition of CD200Fc to the incubation medium significantly attenuated the Aβ-induced
changes in these four parameters (+P< 0.05; ++P< 0.01; +++P< 0.001).
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present evidence, therefore, suggests that CD200Fc
reverses several aspects of microglial function, specific-
ally their secretory and phagocytic ability.
Recent data from this laboratory have shown that
intracerebroventricular injection of CD200Fc attenuated
the age-related and LPS-induced deficit in LTP in the
dentate gyrus of urethane-anaesthetized rats in vivo [5].
CD200Fc decreased MHCII mRNA in both models pro-
viding further evidence that LTP is sustained when
microglia are in a quiescent state [31,32]. However, the
modulatory effects of CD200R activation on inflamma-
tory changes, and particularly microglial/macrophage
activation, are perhaps best characterized in EAE. In
CD200-deficient mice, the onset of the symptoms is
more rapid and the inflammatory changes, including ac-
tivation of macrophages and microglia, are more pro-
nounced [9]. In contrast, the attenuated disease observed
in Wlds mice has been attributed to the increased ex-
pression of CD200 on neurons in these mice [33].
Similarly, CD200Fc has been shown to attenuate the
inflammatory changes associated with EAE [13], while
a blocking anti-CD200 antibody reversed the attenu-
ated disease in Wlds mice [33] and resulted in exag-
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Figure 5 Dok2 mediated the effects of CD200Fc. Efficiency of Dok2 siRNA knock-down was measured by western blot (A) and
immunofluoresence (B). Incubation of microglia in the presence of Aβ significantly increased expression of CD40 mRNA (C) and release of IL-1β
(D) and TNFα (E; **P< 0.01; ***P< 0.001; ANOVA; n = 6). Addition of CD200Fc to the incubation medium significantly attenuated these
Aβ-induced changes (+P< 0.05; ++P< 0.01). Whereas non-target siRNA exerted no significant effect, Dok2 siRNA prevented the action of CD200Fc
so that there was a significant difference in CD40 mRNA and in supernatant concentrations of IL-1β and TNFα prepared from cells treated with
Aβ+CD200Fc compared with those treated with Aβ+CD200Fc +Dok2 siRNA (}P< 0.05; ANOVA).
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macrophages in the spinal cord of rats in which EAE
was induced [34]. Recent data have indicated that a
CD200R blocking antibody also enhanced microglial
activation and neurodegenerative changes in a mouse
model of Parkinson’s disease [35]. These preclinical
data have been broadly supported by studies under-
taken in clinical samples. Thus, increased expression of
markers of macrophage or microglial activation and in-
flammatory cytokines, accompanied by decreased ex-
pression of CD200 has been observed in active and
inactive lesions in the CNS obtained from postmortem
tissue of individuals with multiple sclerosis [6] and a
decrease in expression of CD200 has been reported in
areas of the brain which exhibit pathology in Alzhei-
mer’s disease [36].
It is consistently reported that factors which induce in-
flammatory changes have a negative impact on synaptic
plasticity and, therefore Aβ, like LPS, inhibits LTP
in vivo and in vitro [20,37], whereas factors that block
the Aβ- and LPS-induced inflammatory changes, such as
the anti-inflammatory cytokine, IL-4, exerts a restorative
effect [38]. Here we observed that LTP is impaired in
area CA1 following application of Aβ to hippocampal
slices and, importantly, that when Aβ was applied to
slices in the presence of CD200Fc, LTP was partially
restored. This finding provides additional support for
the hypothesis that the negative effect of inflammation
on synaptic plasticity can be alleviated when the inflam-
matory changes are suppressed. However, it also reveals
that modulating the Aβ-induced inflammatory changes
by directly down-regulating microglial activity with
CD200Fc exerts a marked effect on neuronal function.
Conclusion
This study highlights the negative effect that activated
microglia exert on synaptic plasticity but, importantly, it
identifies the fact that activation of CD200R or triggering
phosphorylation of Dok2 in microglia provides a poten-
tial target for attenuating the effects of Aβ on neurons.
Abbreviations
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Figure 6 CD200Fc relieves the Aβ-mediated deficit in LTP. A. Perfusion of Aβ[1–40] (500 nM) for 40 minutes prior to TBS (arrow) significantly
impaired LTP in area CA1 of hippocampal slices (n = 6) compared with controls (n = 5; P< 0.001). Pre-treatment with CD200Fc (2 mg/ml) for 20
minutes prior to application of Aβ[1–40] significantly increased the level of LTP compared with values obtained in the presence of Aβ alone (n = 4;
P< 0.05; ANOVA). B. Sample EPSP traces (average of four consecutive recordings; scale bar: 1 mV/20 ms), taken immediately prior to application
of TBS and 60 minutes post-LTP induction, in control and Aβ-treated slices, and from a slice co-treated with CD200Fc and Aβ.
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